RBC keeps target for Sartorius Stedim stock at EUR 210
Published on 10/12/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- RBC Capital Markets maintained an Outperform rating and a EUR 210.00 target on October 6, 2026.
- Sartorius Stedim reported EUR 1.527 billion in first-half 2026 revenue and a 31.40 percent EBITDA margin.
- The stock was at EUR 213.70 at Lang & Schwarz on October 12, 2026, plus 0.42 percent versus the Xetra close of October 9, 2026.
- The next scheduled report is the 9M 2026 results on October 22, 2026.
Sartorius Stedim (ISIN FR0013154002) was trading at EUR 213.70 at Lang & Schwarz on October 12, 2026 at 10:41 a.m. CEST, plus 0.42 percent versus the Xetra close of October 9, 2026 at EUR 212.80. finanzen.ch reported that RBC Capital Markets maintained its Outperform rating and a EUR 210.00 price target on October 6, 2026.
Three events frame the recovery
On July 22, 2026, Sartorius Stedim reported first-half revenue of EUR 1.527 billion and an EBITDA margin of 31.40 percent, according to Ideal Investisseur. On October 1, 2026, finanzen.ch reported that Goldman Sachs raised its target from EUR 208.00 to EUR 223.00 while keeping a Buy rating. RBC's October 6, 2026 update, with its EUR 210.00 target, is the latest of the three events.
When are the next results?
The next scheduled milestone is October 22, 2026, when Sartorius Stedim plans to publish its 9M 2026 results, according to the company's investor-relations page. That date gives the market a defined test for whether the first-half recovery can continue into the third quarter.
What does the target spread imply?
The analyst signals are constructive but not identical. Goldman Sachs' EUR 223.00 target lies 4.35 percent above the Lang & Schwarz price of EUR 213.70, while RBC's EUR 210.00 target sits EUR 3.70 below it. The gap matters because the stock is also EUR 12.20 below its 52-week high of EUR 225.00, leaving valuation and execution closely linked.
Stock quote and investor context
Sartorius Stedim supplies instruments, consumables and services for biopharmaceutical development and production. Its first-half revenue of EUR 1.527 billion and 31.40 percent EBITDA margin provide the operating reference for the October results date, while the EUR 210.00 to EUR 223.00 target range shows how analysts differ on the pace of recovery.
The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.
Sartorius Stedim stock facts
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- Ticker: DIM
- Primary exchange: Euronext Paris
- Price Lang & Schwarz (as of October 12, 2026, 10:41 a.m. CEST): EUR 213.70
- Change versus Xetra close (October 9, 2026): plus 0.42 percent
- Xetra close (October 9, 2026): EUR 212.80
- Market capitalization: EUR 20.8 billion (as of October 12, 2026)
- 52-week range: EUR 150.00-225.00 (as of October 12, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: SBF 120
- Next earnings date: October 22, 2026
Market context: Market report CAC 40.
